Enzo Biochem - 43 Year Stock Price History | ENZ
Historical daily share price chart and data for Enzo Biochem since 1980 adjusted for splits. The latest closing stock price for Enzo Biochem as of March 20, 2023 is 2.24.
- The all-time high Enzo Biochem stock closing price was 122.00 on January 21, 2000.
- The Enzo Biochem 52-week high stock price is 3.06, which is 36.6% above the current share price.
- The Enzo Biochem 52-week low stock price is 1.00, which is 55.4% below the current share price.
- The average Enzo Biochem stock price for the last 52 weeks is 2.10.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Enzo Biochem Historical Annual Stock Price Data |
| Year |
Average Stock Price |
Year Open |
Year High |
Year Low |
Year Close |
Annual % Change |
| 2023 |
1.3549 |
1.3800 |
2.2500 |
1.0000 |
2.2400 |
56.64% |
| 2022 |
2.5085 |
3.1300 |
3.4700 |
1.1600 |
1.4300 |
-55.45% |
| 2021 |
3.2529 |
2.6600 |
4.0900 |
2.6100 |
3.2100 |
27.38% |
| 2020 |
2.3941 |
2.7600 |
3.8700 |
1.8200 |
2.5200 |
-4.18% |
| 2019 |
3.3306 |
2.8000 |
4.3100 |
2.5400 |
2.6300 |
-5.40% |
| 2018 |
5.2278 |
8.2500 |
8.3600 |
2.4600 |
2.7800 |
-65.89% |
| 2017 |
9.2622 |
7.1400 |
11.7900 |
6.4000 |
8.1500 |
17.44% |
| 2016 |
5.5990 |
4.6900 |
7.4800 |
4.0600 |
6.9400 |
54.22% |
| 2015 |
3.3382 |
4.4500 |
4.9500 |
2.4300 |
4.5000 |
1.35% |
| 2014 |
4.4767 |
2.9200 |
6.0800 |
2.6900 |
4.4400 |
52.05% |
| 2013 |
2.4717 |
2.7500 |
3.1000 |
1.9400 |
2.9200 |
8.15% |
| 2012 |
2.2276 |
2.3700 |
3.0500 |
1.4600 |
2.7000 |
20.54% |
| 2011 |
3.5622 |
5.5000 |
5.7900 |
1.9900 |
2.2400 |
-57.58% |
| 2010 |
4.8886 |
5.6700 |
6.6700 |
3.3700 |
5.2800 |
-1.86% |
| 2009 |
5.0182 |
5.1000 |
7.6600 |
2.9000 |
5.3800 |
10.02% |
| 2008 |
9.3999 |
12.9800 |
14.8300 |
3.5000 |
4.8900 |
-61.62% |
| 2007 |
14.3258 |
14.5700 |
18.6500 |
10.0500 |
12.7400 |
-10.72% |
| 2006 |
12.8201 |
12.5500 |
16.0000 |
9.3000 |
14.2700 |
14.90% |
| 2005 |
15.4169 |
19.3000 |
19.3000 |
12.4200 |
12.4200 |
-36.21% |
| 2004 |
16.2483 |
17.9500 |
20.4500 |
11.7100 |
19.4700 |
8.71% |
| 2003 |
17.7666 |
14.6000 |
28.4300 |
11.5200 |
17.9100 |
27.93% |
| 2002 |
16.6054 |
24.5500 |
25.7200 |
11.6500 |
14.0000 |
-40.43% |
| 2001 |
22.9783 |
21.8100 |
34.9800 |
13.9500 |
23.5000 |
-5.55% |
| 2000 |
53.9979 |
44.0000 |
122.0000 |
20.4400 |
24.8800 |
-45.91% |
| 1999 |
17.7067 |
10.3800 |
46.8800 |
8.1250 |
46.0000 |
346.17% |
| 1998 |
12.2603 |
14.6300 |
16.2500 |
6.5000 |
10.3100 |
-29.53% |
| 1997 |
15.9713 |
18.5000 |
20.6300 |
13.0000 |
14.6300 |
-19.26% |
| 1996 |
17.3435 |
19.7500 |
21.1300 |
14.2500 |
18.1200 |
-5.87% |
| 1995 |
14.2192 |
11.3800 |
23.7500 |
9.6250 |
19.2500 |
72.96% |
| 1994 |
12.4075 |
16.0000 |
19.3800 |
7.7500 |
11.1300 |
-29.91% |
| 1993 |
10.8082 |
7.7500 |
19.8800 |
6.5000 |
15.8800 |
115.32% |
| 1992 |
5.0900 |
3.3700 |
7.5000 |
3.2500 |
7.3750 |
96.67% |
| 1991 |
1.6484 |
1.8800 |
7.8800 |
0.5000 |
3.7500 |
76.06% |
| 1990 |
3.0223 |
3.8700 |
4.5000 |
1.7500 |
2.1300 |
-41.16% |
| 1989 |
3.6294 |
3.1300 |
4.8700 |
2.6300 |
3.6200 |
11.38% |
| 1988 |
3.9506 |
4.0000 |
4.8700 |
2.5000 |
3.2500 |
-13.33% |
| 1987 |
8.4392 |
8.7500 |
12.1200 |
3.2500 |
3.7500 |
-57.14% |
| 1986 |
12.7321 |
12.1200 |
18.7500 |
8.3800 |
8.7500 |
-29.26% |
| 1985 |
14.1660 |
15.2500 |
21.0000 |
10.3700 |
12.3700 |
-17.53% |
| 1984 |
16.3823 |
25.6200 |
26.2500 |
12.2500 |
15.0000 |
-39.69% |
| 1983 |
24.7116 |
16.2467 |
33.5000 |
16.2467 |
24.8700 |
40.77% |
| 1982 |
10.3396 |
10.5000 |
17.6667 |
5.5000 |
17.6667 |
66.98% |
| 1981 |
9.2933 |
3.6233 |
15.0800 |
3.4567 |
10.5800 |
192.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.110B |
$0.107B |
|
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
|
